Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX NASDAQ:LUNG NASDAQ:MDAI NASDAQ:NRXS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$1.96-3.9%$2.02$0.76▼$2.73$77.10M1.39104,177 shs87,152 shsLUNGPulmonx$1.62+0.6%$2.80$1.57▼$9.37$65.60M0.43917,083 shs1.15 million shsMDAISpectral AI$2.40-1.2%$2.36$0.82▼$3.25$61.52M0.9532,818 shs218,074 shsNRXSNeurAxis$2.51+0.8%$2.56$1.33▼$6.20$18.11M3.1702,347 shs57,960 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical-3.92%+2.62%-17.30%+66.10%+94.06%LUNGPulmonx+0.62%-11.96%-40.66%-52.21%-72.35%MDAISpectral AI-1.23%-3.23%-15.49%+93.55%+70.21%NRXSNeurAxis+0.80%-4.20%+1.62%+25.50%-14.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical1.1 of 5 stars0.03.00.04.20.01.70.6LUNGPulmonx3.8085 of 5 stars4.33.00.00.02.03.31.3MDAISpectral AI2.312 of 5 stars3.72.00.00.01.23.30.0NRXSNeurAxis2.8486 of 5 stars3.55.00.00.00.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate BuyN/AN/ALUNGPulmonx 2.56Moderate Buy$7.66373.10% UpsideMDAISpectral AI 3.33Buy$4.7597.92% UpsideNRXSNeurAxis 3.00Buy$7.00178.88% UpsideCurrent Analyst Ratings BreakdownLatest NRXS, APYX, LUNG, and MDAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/1/2025LUNGPulmonxWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.00 ➝ $3.007/31/2025LUNGPulmonxLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.007/31/2025LUNGPulmonxStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $5.007/31/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $16.007/31/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$9.00 ➝ $2.506/16/2025NRXSNeurAxisCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/16/2025NRXSNeurAxisCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$7.005/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.15(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$48.10M1.54N/AN/A$0.38 per share5.16LUNGPulmonx$83.79M0.79N/AN/A$1.70 per share0.95MDAISpectral AI$29.58M2.05N/AN/A($0.32) per share-7.50NRXSNeurAxis$2.93M6.17N/AN/A($0.27) per share-9.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$23.46M-$0.55N/AN/AN/A-42.37%-156.85%-31.92%N/ALUNGPulmonx-$56.39M-$1.43N/AN/AN/A-62.88%-69.76%-36.26%N/AMDAISpectral AI-$15.31M-$0.54N/AN/AN/A-30.75%N/A-11.37%8/12/2025 (Estimated)NRXSNeurAxis-$14.63M-$1.19N/A∞N/A-492.76%N/A-641.25%8/12/2025 (Estimated)Latest NRXS, APYX, LUNG, and MDAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MDAISpectral AI-$0.07N/AN/AN/A$5.44 millionN/A8/7/2025Q2 2025APYXApyx Medical-$0.0933-$0.09+$0.0033-$0.09$11.69 million$11.37 million7/30/2025Q2 2025LUNGPulmonx-$0.40-$0.38+$0.02-$0.38$23.46 million$23.86 million5/8/2025Q1 2025APYXApyx Medical-$0.13-$0.10+$0.03-$0.10$9.39 million$9.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/AMDAISpectral AIN/AN/AN/AN/AN/ANRXSNeurAxisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical3.215.454.64LUNGPulmonx0.545.354.29MDAISpectral AIN/A1.411.37NRXSNeurAxisN/A0.240.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%LUNGPulmonx91.04%MDAISpectral AI67.08%NRXSNeurAxis11.77%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%LUNGPulmonx6.80%MDAISpectral AI30.70%NRXSNeurAxis26.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.79 million32.05 millionOptionableLUNGPulmonx25040.75 million37.98 millionOptionableMDAISpectral AI8325.32 million17.55 millionNot OptionableNRXSNeurAxis197.22 million6.09 millionNot OptionableNRXS, APYX, LUNG, and MDAI HeadlinesRecent News About These CompaniesComparing Precision Optics (OTCMKTS:PEYE) & NeurAxis (NASDAQ:NRXS)July 30, 2025 | americanbankingnews.comNeuraxis ends Masimo license agreement and launches employee stock planJuly 5, 2025 | investing.comNeurAxis, Inc. (NASDAQ:NRXS) Major Shareholder Acquires $800,001.00 in StockJuly 4, 2025 | insidertrades.comNeurAxis, Inc. Ends Agreement with Masimo CorporationJuly 3, 2025 | tipranks.comNeurAxis, Inc. (NRXS) Latest Stock News & Headlines - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comThe Zacks Analyst Blog Highlights Microsoft, NVIDIA, Bank of America, BK Technologies and NeurAxisJune 27, 2025 | sharewise.comSNeurAxis, Inc. Expands Insurance Coverage for IB-Stim Therapy, Enhancing Access for Patients with Abdominal PainJune 17, 2025 | quiverquant.comQNeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered LivesJune 17, 2025 | globenewswire.comNeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBSJune 10, 2025 | finance.yahoo.comNeurAxis, Inc. Announces Inclusion of PENFS Technology in Pediatric Gastroenterology Guidelines for Functional Abdominal Pain TreatmentJune 10, 2025 | quiverquant.comQNeurAxis, Inc. Approves Key Proposals at Annual MeetingJune 4, 2025 | tipranks.comNeurAxis, Inc. Completes $5 Million Registered Direct Offering to Support Growth of IB-Stim TherapyMay 22, 2025 | quiverquant.comQNeurAxis Announces Closing of $5.0 Million Registered Direct OfferingMay 22, 2025 | globenewswire.comNeurAxis, Inc. Announces $5 Million Stock OfferingMay 22, 2025 | tipranks.comNeurAxis, Inc. Receives $1 Million from Warrant ExercisesMay 21, 2025 | tipranks.comNeurAxis Announces $5.0 Million Registered Direct OfferingMay 21, 2025 | finance.yahoo.comNeurAxis Announces $5.0 Million Registered Direct OfferingMay 21, 2025 | globenewswire.comNeuraxis Stock Price, Quotes and Forecasts | AMEX:NRXS | BenzingaMay 21, 2025 | benzinga.comNeurAxis Stock Doubles with FDA Clearance for IB-StimMay 21, 2025 | marketwatch.comNeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea SymptomsMay 21, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025View Why the American Eagle Stock Rally Isn't Just Speculation America Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Super Micro Computer Sees Unusual Volume—Catalyst Ahead?By Gabriel Osorio-Mazilli | July 25, 2025View Super Micro Computer Sees Unusual Volume—Catalyst Ahead?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?By Leo Miller | July 31, 2025View Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?NRXS, APYX, LUNG, and MDAI Company DescriptionsApyx Medical NASDAQ:APYX$1.96 -0.08 (-3.92%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.92 -0.04 (-1.84%) As of 08/7/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Pulmonx NASDAQ:LUNG$1.62 +0.01 (+0.62%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.62 +0.00 (+0.31%) As of 08/7/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Spectral AI NASDAQ:MDAI$2.40 -0.03 (-1.23%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$2.42 +0.02 (+1.04%) As of 08/7/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.NeurAxis NASDAQ:NRXS$2.51 +0.02 (+0.80%) Closing price 08/7/2025 03:56 PM EasternExtended Trading$2.48 -0.03 (-1.20%) As of 08/7/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
